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Abstract
Background: The irinotecan (CPT-11) causes intestinal mucositis and diarrhea that may be related to changes in
the enteric nervous system (ENS). In inflammatory condition, mast cells release a variety of pro-inflammatory
mediators that can interact with the ENS cells. It has not been explored whether CPT-11 is able to alter the
enteric glial and neuronal cell, and the role of mast cells in this effect. Therefore, this study was conducted
to investigate the effect of CPT-11 on the enteric glial and neuronal cells, as well as to study the role of
mast cells in the CPT-11-induced intestinal mucositis.
Methods: Intestinal mucositis was induced in Swiss mice by the injection of CPT-11 (60 mg/kg, i.p.) once a day for
4 days following by euthanasia on the fifth day. To investigate the role of mast cells, the mice were pretreated with
compound 48/80 for 4 days (first day, 0.6 mg/kg; second day, 1.0 mg/kg; third day, 1.2 mg/kg; fourth day, 2.4 mg/
kg) to induce mast cell degranulation before the CPT-11 treatment.
Results: Here, we show that CPT-11 increased glial fibrillary acidic protein (GFAP) and S100β gene and S100β
protein expressions and decreased HuC/D protein expression in the small intestine segments. Concomitantly,
CPT-11 enhanced tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels and inducible nitric oxide synthase
(iNOS) gene expression, associated with an increase in the total number macrophages (positive cells for ionized
calcium-binding adapter molecule, Iba-1) and degranulated mast cells in the small intestine segments and caused
significant weight loss. The pretreatment with compound 48/80, an inductor of mast cells degranulation,
significantly prevented these CPT-11-induced effects.
Conclusions: Our data suggests the participation of mast cells on the CPT-11-induced intestinal mucositis,
macrophages activation, enteric reactive gliosis, and neuron loss.
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Background
Irinotecan (CPT-11) is a topoisomerase I inhibitor, broadly
used to treat lung, gastric, cervical, ovarian, and colorectal
cancers [1]. The active metabolite, SN-38, induces ir-
reversible deoxyribose nucleic acid (DNA) damage in
tumor cells, and its accumulation in the intestinal
mucosa is thought to be responsible for enterotoxicity
[2]. Irinotecan-based cancer chemotherapy regimens
induce intestinal mucositis in 25% of patients, which
exhibit severe mucosal inflammation and life-threatening
diarrhea. [3, 4] There has been increasing interest in the
pathobiology of antineoplastic-induced intestinal mucosi-
tis, since it compromises the treatment outcome and may
increase morbidity and mortality [5].
Previous reports demonstrated that patients using
chemotherapeutic drugs, such as CPT-11, present gas-
trointestinal complications, such as intestinal dysmotility
[6]. Delayed gastric empty and increased intestinal
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contractility were associated with 5-Fluorouracil-induced
intestinal mucositis in mice [7]. The involvement of
many inflammatory mediators, such as nitric oxide (NO)
[8], interleukin-18 (IL-18) [9], interleukin-33 (IL-33)
[10], tumor necrosis factor-α (TNF-α), interleukin-1β
(IL-1β), and keratinocyte chemoattractant (KC) [11] have
been implicated on these side effects, leading to intes-
tinal damage, characterized by shortened villi, loss of
crypts architecture, and intense inflammatory cell infil-
trate. The consequences of irinotecan in the enteric ner-
vous system (ENS), a ganglionated neuronal network
that resides within the gut wall, however, have not been
studied and merit further investigation.
Pronounced reduction of total neuron number, associ-
ated with an increase in the number of enteric glia cells
(EGC) in ENS is reported in several bowel inflammatory
disorders, such as celiac disease [12], inflamed segments
of Crohn’s diseases [13], and ulcerative colitis [14–17].
Crohn’s disease [18] and irritable bowel syndrome [19]
are both characterized by intense inflammation and by
augmented mast cell infiltration. Mast cell mediators
release, such as histamine, tryptase, prostaglandin D2
(PGD2) and interleukin-6 (IL-6) stimulate intestinal secre-
tion and motility [20, 21]. Furthermore, mast cells media-
tors were already implicated in neuronal death [22].
In this study, we investigated whether ENS is affected
by CPT-11-induced intestinal mucositis, and the poten-
tial participation of mast cells in this effect. We demon-
strated that CPT-11 enhanced and activated EGCs,
reduced the neuron population, and augmented the
number and activation of mast cells in the small intes-
tine. These effects were prevented by previous degranu-
lation of mast cells.
Methods
Animals
Seventy-two Swiss mice, weighing 25–30 g, were housed
in temperature-controlled rooms under 12-h light-dark
cycles. The animals received water and food ad libitum.
The animal treatments were conducted in accordance
with the Guidelines for Institutional and Animal Care
and Use of Federal University of Ceará, Brazil.
All procedures involving animals were approved by the
Federal University of Ceará Committee on the ethical
treatment of research animals (protocol no. 84/2015).
Induction of experimental intestinal mucositis
Intestinal mucositis was induced in Swiss mice, as previ-
ously described [23], by four injections, once daily, of
irinotecan (CPT-11, 60 mg/kg, i.p.). The animals were
euthanized with an overdose of 2% xylazine and 10%
ketamine (10/100 mg/kg; i.p.) 5 days after the first CPT-
11 administration. The body weight was monitored
throughout the experimental periods.
Experimental groups
The mice were randomly divided into four groups: (1)
the control group received intraperitoneal 0.9% saline
solution once daily for 4 days; (2) the CPT-11 group
received irinotecan (CPT-11, 60 mg/kg, i.p.) once daily
for 4 days; (3) the CPT-11 + c48/80 group was pretreated
for 4 days with the mast cell degranulator compound 48/
80 (Sigma-Aldrich) dissolved in PBS (phosphate-buffered
saline; injected with 200 μl/cavity, i.p.), as previously
described in the literature [24], according to the following
schemes: 0.6 mg/kg on the first day; 1.0 mg/kg on the
second day; 1.2 mg/kg on the third day, and 2.4 mg/kg on
the fourth day. The induction of intestinal mucositis by
CPT-11was initiated 24h after the last administration of
compound 48/80, as previously described in the present
work; (4) the c48/80 group was pretreated with compound
48/80, as described, but was not subjected to CPT-11-
induced intestinal mucositis.
Toluidine blue staining
Following euthanasia, 5 days after the first CPT-11 injec-
tion, tissue samples (including the mucosal, submucosal,
muscle, and serosa layer) of each small intestine sections
(duodenum, jejunum and ileum) were collected and
fixed in 10% neutral-buffered formalin, dehydrated, and
embedded in paraffin. Paraffin-embedded tissue sections
were mounted onto slides, deparaffinized with xylene,
incubated for 3 min with toluidine blue solution (1 g of
toluidine blue dissolved in 70% ethanol), washed three
times in distilled water, dehydrated, and mounted. Mast
cell granules stain purple in color due to the presence of
heparin and histamine. For that reason, purple stain was
recognized as a positive staining for mast cells. The total
number of mast cells (degranulated and non-degranulated)
were counted manually, considering six specimens per
group and ten fields per slide (where the highest
number of mast cells was seen), on ×400 magnifica-
tion. The results are expressed as the percentage of
degranulated mast cells.
Western blot analyses
Following euthanasia, 5 days after the first CPT-11 injec-
tion, samples of the three small intestine segments
(duodenum, jejunum, and ileum) were collected and ho-
mogenized in RIPA lysis buffer (25 mM Tris-HCL,
pH 7.6; 150 mM NaCl; 5 mM EDTA; 1% NP40; 1% tri-
ton X-100; 1% sodium deoxilato; 0,1% SDS) and protease
inhibitor (1 μL inhibitor: 100 μL RIPA). For protein ex-
traction, intestinal samples were centrifuged (17 min, 4 °
C, 13,000 rpm), and supernatant was collected. Protein
concentrations were determined through the bicin-
chroninic acid assay (Thermo Fisher Scientific) accord-
ing to the manufacturer`s protocol. SDS-polyacrylamide
gel electrophoresis (10%) was performed using 20 μg of
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protein (previously prepared with laemmli sample buffer,
BioRad) and was denatured at 95 °C for 5 min. There-
after, proteins were transferred to PVDF membrane
(BioRad), blocked with BSA 5% for 1 h, and incubated
overnight with primary antibody (rabbit anti-β actin, 04-
1116, Merck Millipore, 1:500; goat anti-S100β, sc7851,
Santa Cruz Biotechnology; or mouse anti-HuC/D, A21271,
Invitrogen, 1 ug/mL) and secondary antibody (goat anti-
rabbit, 656120, Invitrogen, 1:1000; rabbit anti-goat, A16142,
Invitrogen, 1:2000; or goat anti-mouse IgG, 626520, Invi-
trogen, 1:1000). Membranes were incubated using the
ECL system according to the manufacturer’s instruc-
tions (BioRad), and the chemiluminescence signal was
detected using the ChemiDoc™ XRS system (BioRad).
The densitometric quantification of western blot bands
was quantified using NIH ImageJ software.
Histopathological analysis
For the histological analysis, tissue samples of each small
intestine segments were collected and fixed in 10%
neutral-buffered formalin, dehydrated, and embedded
in paraffin. Sections (5 μm thick) were obtained for
hematoxylin-eosin staining (H&E) for subsequent examin-
ation using light microscopy (×200). The lengths of the
intestinal villi (six to ten villi per slide; six mice per group)
were determined from digital images captured by a digital
camera coupled to a Leica microscope and were analyzed
using ImageJ 1.4 software (NIH, Bethesda, MD, USA).
Mucosa injuries were assessed using a modification of the
histopathological score system described by Woo et al.
[25] and were graded as follows: score 0, normal histo-
logical findings (no lesion); score 1, <10% crypts contain
individual necrotic cells; score 2, >10% crypts contain nec-
rotic cells, but the crypt architecture is intact; score 3, >10%
crypts contain necrotic cells showing focal loss of crypt
architecture, shortened villi and variable hypertrophy/hiper-
basophilia apparent in the remaining crypt cells; and score
4, same as grade 3 except that the loss of crypt architecture
and villus shortening are more extensive.
Measurement of TNF-α and IL-6 in duodenum and
jejunum
Duodenum and jejunum samples were collected 5 days
after the first injection of CPT-11 for TNF-α and IL-6
measurements using a commercial ELISA kit (R&D Sys-
tem), according to the manufacturer’s instructions. The
results are expressed as picograms per milliliter of tissue.
Immunohistochemistry
Sections of 4 μm were prepared from paraffin-embedded
intestinal tissues. After deparaffinization, antigenic recu-
peration was performed with citrate buffer (pH 6.0) for
20 min in 95 °C. Endogenous peroxidase was blocked with
3% H2O2 for 10 min to reduce non-specific binding. The
sections were then incubated with glial fibrillary acidic
protein (GFAP, IS524, DAKO), S100β (IR504, DAKO),
HuC/D (A21271, Invitrogen, 1μg/mL), or ionized calcium-
binding adapter molecule (Iba-1, ab107159, Abcam, 1:200)
antibody, diluted in DAKO antibody diluent for 1 h. Sec-
tions were then incubated for 30 min with polymer (K4061,
DAKO). The antibody binding sites were visualized by the
incubation with diaminobenzidine–H2O2 (DAB, DAKO)
solution. Sections incubated with antibody diluent, without
the primary antibody included, were considered negative
controls. Brownish color in the cytoplasm (GFAP, S100β, or
HuC/D) or nucleus (HuC/D) was recognized as positive
staining. The quantitative estimation of DAB products from
immunostaining was determined from digital images of at
least ten different areas of each section (from four speci-
mens per group), where the highest number of immu-
nostaining was detected, on ×400 (GFAP and S100β) or
×1000 (HuC/D) magnification, using Adobe Photoshop
software. Quantification of the immunostaining was calcu-
lated dividing the number of positive pixels identified by
DAB staining by the total number of pixels per image, as
previously described [26]. The Iba-1 positive cells were
manually counted from images of the small intestinal
segments (duodenum, jejunum, and ileum), captured using
a digital camera coupled to a Leica microscope, on ×400
magnification. It was considered four specimens per group,
and ten fields per slide.
RNA extraction and cDNA synthesis
The ribonucleic acid (RNA) was isolated from duodenum
segments, collected 5 days after the first administration of
CPT-11, using an established RNA isolation protocol, ac-
cording to the manufacturer’s instructions (PROMEGA).
RNA was quantified by NanoDrop (Thermo Fisher Scien-
tific), and the samples purity was verified by 260/280
ratios >1.8. Complementary DNA (cDNA) was then syn-
thesized from 1 μg RNA, using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems), according
to the manufacturer’s protocol.
TaqMan qPCR
The messenger RNA (mRNA) expression analysis was
performed by TaqMan quantitative PCR (qPCR), accord-
ing to the manufacturer’s instruction, using pre-made
probes (Applied Biosystems, USA), described in Table 1.
All samples were run in duplicate, and the relative
mRNA expression level was determined after normaliz-
ing all values to those of glyceraldehyde-3-phosphate
dehydrogenase (Gapdh). For each sample, the following
reagents were pipetted into a nuclease-free 0.2-mL
microcentrifuge tube: 40 ng of cDNA (diluted ×5; 4 μl),
20x TaqMan gene expression assay (1 μl of S100β, GFAP,
inducible nitric oxide synthase, iNOS or Gapdh), 2x Taq-
Man gene expression master mix (10 μl), and RNA-free
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water (5 μl). The reaction components were mixed
by inverting the tube several times followed by a
brief centrifugation. The 20 μl of PCR reaction mix
(corresponded to the final volume of each reaction)
were transferred into each well of a 96-well reaction
plate. The plate was sealed and briefly centrifuged.
The thermocycler parameters were set at 50 °C for
2 min, followed by 95 °C for 10 min, 40 cycles of
95 °C for 15 s, and 60 °C for 60 s. The fold changes
were calculated using the ΔΔCt comparative quantifi-
cation method.
Statistical analysis
Data are presented as means ± standard error of the
mean (S.E.M.) or as medians when appropriate. Student’s
t test, one-way or two-way analysis of variance followed
by Bonferroni test were used to compare means, and
Kruskal–Wallis and Dunn’s tests were used to compare
medians. Data analyses were performed with GraphPad
Prism 6.0 software (GraphPad Software Inc., USA). A
p value < 0.05 was considered significant.
Results
CPT-11 increases the number of mast cells in the small
intestine
Considering that mediators released from activated mast
cell are involved in neuron death [22], we investigated
whether CPT-11 could increase the number of mast cells
in the small intestine and induce their degranulation,
using toluidine blue staining. We found that CPT-11 en-
hanced the total and degranulated mast cell number in
the small intestine of mice subjected to CPT-11-induced
intestinal mucositis when compared with the control
group (Fig. 1a, Additional file 1: Figure S1).
CPT-11 enhances the expression of S100β and reduces
HuC/D in the small intestine
Western blotting for glial (S100β) and neuron (HuC/D)
markers was performed to evaluate the effect of CPT-11
on the enteric glial cells and neurons, respectively. CPT-
11 enhanced the S100β protein expression (Fig. 1b) and
decreased the HuC/D protein expression in the three
segments of the small intestine when compared with the
control group (Fig. 1c).
Pre-degranulation of mast cells prevents the CPT-11-
induced histological changes
In order to investigate whether the expression of S100β
and HuC/D, markers of enteric glia and neuron, respect-
ively, are altered in the ENS of animals treated with
CPT-11 and to investigate the role of mast cells in this
effect, the mice were previously pretreated with 48/80, a
compound that promotes mast cells degranulation, be-
fore the first injection of CPT-11 to prevent the mast
cell degranulation. The degranulation of mast cells by
compound 48/80 was previously confirmed by histo-
logical analysis of each small intestine section stained
with toluidine blue (data not shown). In addition, mast
cells were immunostained using an anti-tryptase anti-
body. CPT-11 increased (p < 0.05) the number of tryp-
tase positive immunostaining cells in the duodenum and
jejunum segments, but not in the ileum (p > 0.05), when
compared with control group (Additional file 2: Figure
S2). The pretreatment with compound 48/80 prevented
the CPT-11-induced increase in the tryptase expression
in both duodenum and jejunum sections (Additional
file 2: Figure S2).
The histopathology of the small intestine segments
(duodenum, jejunum, and ileum) of animals subjected to
CPT-11-induced intestinal mucositis showed severe de-
struction of the crypts, villus shortening (Fig. 2m–o),
vacuolization of epithelial and smooth muscle cells, and
intense infiltration of inflammatory cells into the mu-
cosa, resulting in high histological scores (Fig. 2d–f;
Table 2), when compared with the group not subjected
to CPT-11-induced intestinal mucositis (control group;
Fig. 2a–c; Table 2). The pretreatment with compound
48/80 was able to prevent the villus atrophy in the
jejunum (Fig. 2n), but neither in the duodenum (Fig. 2m)
nor in the ileum (Fig. 2o). Compound 48/80 also pre-
vented the destruction of the crypts, and the infiltration
of inflammatory cells into the mucosa of the three small
intestine segments (Fig. 2g–i), resulting in significant
differences in the histological scores (Table 2) between
CPT-11 + c48/80 and CPT-11 groups observed in jejunal
segments. Compound 48/80 by itself did not cause any
Table 1 Description of TaqMan probe used for the detection of
target genes in the experiment
GFAP (glial fibrillary acidic protein)
ID assay Mm01253033_m1
TaQman probe AGAAAACCGCATCACCATTCCTGTA
Amplicon length: 75
S100β (S100 protein, beta polypeptide, neural)
ID assay Mm00485897_m1
TaQman probe CTTCCTGGAGGAAATCAAGGAGGAGCAG
Amplicon length: 69
iNOS (nitric oxide synthase 2, inducible)
ID assay Mm00440502_m1
TaQman probe GCCTTGTGTCAGCCCTCAGAGTACA
Amplicon length 66
Gapdh (Gliceraldehyde-3 phosphate dehydrogenase)
ID assay Mm99999915_g1
TaQman probe GGTGTGAACGGATTTGGCCGTATTG
Amplicon length: 109
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damage to the small intestine, as illustrated by repre-
sentative photomicrographs of duodenum (Fig. 2j),
jejunum (Fig. 2k), and ileum (Fig. 2l) of a mouse treated
with this compound. No significant differences were
found between the c48/80 and the control groups
(Table 2).
Pre-degranulation of mast cells prevents the CPT-11-
induced macrophages activation in duodenum and
jejunum
To further test the role of CPT-11-mediated mast
cell degranulation on the macrophages activation, we
performed immunohistochemistry to Iba1, an established
marker for activated macrophages, in duodenum, jejunum,
and ileum sections. Among the three small intestine
segments of the control group, jejunum displayed
the greatest (p < 0.05) number of Iba1 positive im-
munostaining cells. CPT-11 enhanced (p < 0.05) the
number of Iba1-positive immunostaining cells in the
three small intestine segments, but mostly in the
ileum (p < 0.05), when compared with control group
(Fig. 3). The pretreatment with compound 48/80
prevented the CPT-11-induced increase in the Iba1
expression in the three small intestine segments
evaluated. Taken together, these results suggest that
CPT-11 induces macrophage activation, and this ef-
fect is dependent on the previous release of mast
cell mediators (Fig. 3).
Fig. 1 CPT-11 induces mastocytosis and alters S100β and HuC/D protein expression in small intestine. a Total and degranulated mast cells were
count in the duodenum, jejunum, and ileum in ten microscope field (×400)/slide per mice from six mice in each group. Bars represent mean ±
SEM of number of mast cell/field or percentage of degranulated mast cell per field. #p < 0.05 versus control group. b Representative images of
western blot showing S100β and beta-actin (loading control) protein expression. Quantitative analysis indicated that CPT-11 increased S100β
protein expression in the small intestine. c Representative images of western blot showing HuC/D and beta-actin (loading control) protein
expression. Quantitative analysis indicated that CPT-11 decreased HuC/D protein expression in the small intestine. Bars represent mean ± SEM for
six tissue samples in each group. #p < 0.05 versus control group. Student’s t test
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Pre-degranulation of mast cells prevents the CPT-11-
induced inflammation and weight loss
In order to reinforce that the mast cell pre-degranulation
could be able to prevent the CPT-11-induced inflamma-
tion, we assessed the levels of TNF-α and IL-6 in the duo-
denum and jejunum. We found that the pretreatment
with compound 48/80 prevented (p < 0.05) the increase in
both TNF-α (Fig. 4a) and IL-6 (Fig. 4b) levels, induced by
CPT-11, since significant differences were found between
CPT-11 + c48/80 and CPT-11 groups. Moreover, the
pretreatment with compound 48/80 prevented the in-
crease in the iNOS genic expression, induced by CPT-11,
in the duodenum (Fig. 4c). It must be noted that the
administration of compound 48/80 alone (not followed by
CPT-11 administrations) had no effect on the levels of
TNF-α, IL-6, or iNOS genic expression in the duodenum,
since no statistical differences were detected between c48/
80 and control groups. On the other hand, compound 48/
80 itself induced an increase in the TNF-α and IL-6 levels
in the jejunum compared to the control group.
Fig. 2 Effects of the mast cells pre-degranulation in the intestinal histopathological analysis and villus height: duodenum, jejunum, and ileum of
controls (untreated); animals with CPT-11-induced intestinal mucositis; pretreated with c48/80 and submitted to CPT-11-induced intestinal mucositis or
treated only with c48/80. d–f CPT-11 induces shortening of the villus (green arrows), loss of crypt architecture (brown arrows), intense inflammatory cell
infiltrate (blue arrows), and cell vacuolization (black arrows) in duodenum, jejunum, and ileum. Hematoxylin and eosin; scale bar correspond to 100 μm in all
figures (a–l). Segments of duodenum (m), jejunum (n), and ileum (o) were collected for measurement of villus height (ten villus/slide). Bars represent mean
± SEM of eight mice in each group. #p< 0.05 versus control group, *p< 0.05 versus CPT-11 group. One-way ANOVA followed by Bonferroni
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The pretreatment with compound 48/80 prevented the
CPT-11-induced weight loss, while the administration of
compound 48/80 alone had no effect on this parameter
(Fig. 4d).
Pre-degranulation of mast cells prevents the CPT-11-
induced reactive gliosis and neuron loss
To examine whether the CPT-11-induced reactive gliosis
might be mediated by mast cells, GFAP and S100β
expressions were investigated by immunohistochemistry
in the small intestine sections collected from mice pre-
treated, or not, with compound 48/80 before the CPT-
11 administrations. An increased GFAP immunostaining
was clearly observed in mucosa, submucosa, and my-
enteric plexuses of the duodenum of mice subjected to
CPT-11-induced intestinal mucositis (CPT-11 group)
when compared with the control group (Fig. 5a). The
pretreatment with compound 48/80 (p < 0.05) prevented
the increase of both GFAP and S100β-positive cells in
the duodenum of the CPT-11 + c48/80 group when
compared with CPT-11 group (Fig. 5a, b).
To investigate the participation of mast cells in the
CPT-11-induced neuron loss, immunohistochemistry to
HuC/D was performed in the intestine sections collected
from mice pretreated, or not, with compound 48/80.
CPT-11 induced a decrease (p < 0.05) in the HuC/D
expression when compared with the control group. The
pretreatment with compound 48/80 was able to prevent
(p < 0.05) this effect induced by CPT-11. In addition, no
statistical differences were detected between c48/80 and
control group. Figure 5 shows a considerable reduction
in the HuC/D-positive immunostained cells in the
duodenum of CPT-11 group when compared with
the immunostaining detected in the CPT-11/c48/80
group (Fig. 5a, b).
Pre-degranulation of mast cells prevents the CPT-11-
induced upregulation of S100β and GFAP gene expression
and S100β protein expression
It was observed that a significant increase in the GFAP
and S100β genic expression in the duodenum of animals
subjected to CPT-11-induced intestinal mucositis (CPT-
11 group) compared with control group (Fig. 6a). The
pretreatment with compound 48/80 was able to prevent
(p < 0.05) this effect, since significant differences were
found between the CPT-11 and CPT-11/c48/80 groups.
Moreover, it was observed that an increase in the
S100β protein expression in the duodenum of mice
subjected to CPT-11-induced intestinal mucositis when
compared with normal mice (control group). This effect
was prevented by the pretreatment with compound 48/
80. A significant reduction in the S100β protein expres-
sion was observed in the duodenum of CPT-11 + 48/80
group, when compared to the non-pretreated group
(CPT-11) (Fig. 6b). The compound 48/80 itself had no
effect in the GFAP and S100β expressions since no
significant differences were found between c48/80 and
control groups (Fig. 6a, b).
Discussion
In the present study, we provide sufficient evidence to
suggest that mast cells activation makes a significant
contribution to the pathophysiological processes associ-
ated with CPT-11-induced intestinal mucositis through
the release of pro-inflammatory mediators and activation
of glial cells, detected by increased expression of GFAP
and S100β. These mechanisms might have an impact on
intestinal dysfunction due to neuronal injury.
The CPT-11-induced intestinal damage is indicated in
the current work by shortened villi, loss of crypts ar-
chitecture, and intense inflammatory cell infiltrate, in
accordance with previous studies described in the litera-
ture [9, 10, 27, 28]. The participation of neutrophils and
macrophages in the pathogenesis of CPT-11-induced
intestinal mucositis had been reported [9, 10]. However,
as far as we know, the present study shows for the first
time the involvement of mast cells in the intestinal side
Table 2 Histological scores for intestinal mucositis
Intestine
segments
Experimental groups
Control CPT-11 CPT-11 + c48/80 c48/80
Duodenum 0 (0–0) 4 (2–4)# 2 (1–3)# 0 (0–1)*
Jejunum 0 (0–0) 4 (3–4)# 2 (0–4)#* 0 (0–1)*
Ileum 0 (0–0) 4 (2–4)# 4 (3–4)# 0 (0–0)*
Data represent median values (and range) of scores from 0 to 4 according to
the presence of necrotic cells, loss of crypt architecture, shortened villi, and
hypertrophy/hyperbasophilic in the crypt cells. Data were analyzed by using
Kruskal–Wallis and Dunn’s test (n = 8). #p < 0.05 versus control group, *p < 0.05
versus CPT-11 group
Fig. 3 Mast cell pre-degranulation prevents CPT-11-induced increase
of Iba1 immunostained cells in the small intestine. Graph represents
the mean ± SEM of the number of Iba1 positive cells in duodenum,
jejunum, and ileum in ten microscope field per section from four
mice in each group. White, black, and crosshatch bars represent,
respectively, control, CPT-11, and CPT-11 + c48/80 group. #p < 0.05
versus control group. *p < 0.05 versus CPT-11 group. &p < 0.05 versus
duodenum control group or ileum group control group. **p < 0.05.
One-way ANOVA followed by Bonferroni
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effects of CPT-11, including damage to the ENS. Our data
strongly suggests that CPT-11 has the capacity to induce
morphological changes in the ENS through the release of
mast cells mediators, since we found a significantly
enhanced of total and degranulated mast cells in the three
small intestine segments of mice subjected to CPT-11-
induced intestinal mucositis. Previous studies also docu-
mented mastocytosis associated with irritable bowel
syndrome [19], Crohn’s disease [18], ulcerative colitis [29],
and ischemia-reperfusion injury in animals [30].
In order to investigate the involvement of mast cells in
the pathophysiology of CPT-11-induced intestinal muco-
sitis, the mast cells were previously degranulated by
pharmacological treatment of the animals with the com-
pound 48/80 [31], which leads to impairment of mast
cells function through their degranulation.
Mast cells are normal residents of mucosal tissues, but
their number can change markedly during immune re-
sponses, infections, and other disorders [32]. It is well
established that mast cells, stimulated via the high affinity
receptor for immunoglobulin E (IgE) or via any of mul-
tiple other mechanisms, can release a diverse spectrum of
biologically active mediators, and such products can have
many different effects on immune or structural cells
present in mucosal tissues [32, 33]. These pre-stored me-
diators include vasoactive amines, neutral proteases, and
some preformed cytokines, including TNF-α. Mast cells
are also able to synthesized and secrete a large number of
chemokines, growth factors, and cytokines, including
TNF-α, IL-1β, IL-6, and many others [32]. On the other
hand, inflammatory cytokines can stimulate mast cell
degranulation during inflammatory conditions, where they
Fig. 4 Pre-degranulation of mast cells reduces inflammation in duodenum and jejunum and weight loss of mice submitted to CPT-11-induced
intestinal mucositis. a Pretreatment with c48/80 diminishes TNF-α levels in duodenum and jejunum of mice submitted to CPT-11-induced
intestinal mucositis. b Pretreatment with c48/80 diminishes IL-6 levels in duodenum and jejunum of mice submitted to CPT-11-induced
intestinal mucositis. c Pretreatment with c48/80 decreases iNOS mRNA expression in mice submitted to CPT-11-induced intestinal mucositis.
Bars represent mean ± SEM of six mice in each group. #p < 0.05 versus control group, *p < 0.05 versus CPT-11 group. One-way ANOVA followed
by Bonferroni. d Body weight changes are shown as percentages of the baseline value. Bars represent mean ± SEM of six mice in each group.
#p < 0.05 versus control group, *p < 0.05 versus CPT-11 group. Two-way ANOVA followed by Bonferroni
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are activated by non-allergic triggers [34]. It has been cited
that IL-18 and IL-33, cytokines established involved in the
pathogenesis of intestinal mucositis, may directly activate
mast cells [35, 36].
Mast cell production of chemotactic factors can en-
hance the recruitment of multiple inflammatory cells,
resulting in amplification of the inflammatory reaction.
The mast cell-mediated enhancement of inflammation
could induce damage of host tissues. Accordingly, we
detected that overall intestinal architecture and villi
height were noticeably preserved in the group pretreated
with compound 48/80, associated with decreased levels
of TNF-α, IL-6, and iNOS gene expression, whose role
in the chemotherapy-induced intestinal mucositis had
been previously confirmed [8, 11, 27]. Consistently, the
pre-degranulation of mast cells by compound 48/80 in
models of lethal sepsis resulted in a significant decrease
in the serum levels of TNF-α and interleukin-8 (IL-8)
[24]. Moreover, we demonstrated that CPT-11 activates
macrophages in the three small intestine segments, as
seen by immunohistochemistry. Our results also suggest
that the macrophage activation is associated with mast
cell mediators, especially in duodenum and jejunum.
These data may be a possible explanation to the lower
Fig. 5 Mast cell pre-degranulation prevents CPT-11-induced increase of GFAP and S100β immunostaining and reduction of HuC/D immunostaining in
duodenum of mice. a Representative images illustrating GFAP, S100β, and HuC/D immunostaining in the mucosa, submucosa, and myenteric plexuses.
Scale bar corresponds to 50 μm (GFAP and S100β) or 20 μm (HuC/D). b Graphs represent the mean ± SEM of the percentage of GFAP, S100β, or HuC/
D positive immunostaining in duodenum related to total tissue in five (GFAP and S100β) or ten (HuC/D) microscope field per mice from six mice in
each group quantified using Photoshop. #p < 0.05 versus control group. *p < 0.05 versus CPT-11 group. One-way ANOVA followed by Bonferroni
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effect of the compound 48/80 on the CPT-11-induced
inflammatory response in ileum in comparison with du-
odenum and jejunum segments. The differences among
the small intestine portions, regarding the population
of immune cells, the intestinal microbiota, and the size
of the intestinal villi have been described in the litera-
ture. Villi are longer in duodenum and jejunum, where
most digestion occurs. Ileum, on the other hand, has
markedly shorter villi and lower levels of brush border
enzymes [37]. The accumulation of proinflammatory
macrophages has also been detected in the colon of
animals and patients with inflammatory bowel disease
and has been linked to disease severity and progression
[38]. Taken together, our findings suggest that mast
cells and macrophages might be important sources of
cytokines and enzymes that contribute to gastrointes-
tinal injuries observed in the CPT-11-induced intestinal
mucositis and subsequent loss of body mass. Further
studies are needed to assess the influence of intestinal
mast cells mediators on migration and/or activation of
other inflammatory cells, such as neutrophils. Cyto-
kines have been reported to stimulate intestinal se-
cretion and motility [20, 21] to cause diarrhea and
intestinal dysfunction, which are key signs and symp-
toms of intestinal mucositis [8, 9]. It is well established
that proinflammatory cytokines, such as IL-6 and TNF-
α, are potent inducers of iNOS in a wide variety of cell
types, with consequent production of nitric oxide (NO).
We previously demonstrated that chemotherapy-induced
iNOS activation plays a critical role in the intestinal muco-
sal injury [8, 39]. The participation of NO in the present
study is supported by the increase in the iNOS gene
expression in the intestinal tissue, induced by CPT-11
administrations.
Based on previous studies demonstrating that CPT-11
causes intestinal over-contractility [8, 9], which might be
dependent on cytokines and glial cells, we decided to
investigate the effect of CPT-11 on the ENS, which
autonomously controls gastrointestinal motility, secre-
tion, and blood flow [40]. We found that CPT-11 leads
to a pronounced loss of neurons in the three small intes-
tine segments (jejunum and ileum data not shown).
These findings are supported by the increased expres-
sion of GFAP and S100β, two established markers for
glia cells, associated with a reduced positivity for HuC/
D, a neuronal marker, in the small intestine of mice
subjected to CPT-11-induced mucositis (jejunum and
ileum data not shown), suggesting glial activation and
neuronal loss in the ENS. In accordance with our data,
several inflammatory intestinal diseases, such as celiac
[12], Crohn’s diseases [13], and ulcerative colitis [14, 15]
had been associated with significant enteric nervous
system alterations.
GFAP, the major protein constituent of glial intermedi-
ate filaments in the differentiated fibrous and proto-
plasmic astrocytes of the central nervous system, is
involved in controlling the shape and the movement
of these cells [41, 42]. Increased expression of GFAP
Fig. 6 Mast cell pre-degranulation downregulates CPT-11-induced
GFAP and S100β RNAm expression and S100β protein expression in
duodenum. a GFAP mRNA expression and S100β mRNA expression in
the duodenum were evaluated by qPCR. b S100β protein expression
was evaluated by western blot. Bars represent mean ± SEM of six mice
in each group. #p < 0.05 versus control group, *p < 0.05 versus CPT-11
group. One-way ANOVA followed by Bonferroni
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and S100β represents astroglial activation and gliosis
[41, 43]. In fact, under normal basal conditions, only
subsets of intestinal enteric glia express GFAP, and
most of the enteric glia cells coexpress S100β, proteo-
lipid protein 1 (PLP1), and SRY-related HMG-box10
(Sox10) [44]. Low levels (nanomolar concentrations)
of S100β generally stimulate neuronal pro-survival
responses [45]. High levels (micromolar concentra-
tions), however, promote pro-apoptotic effects [45]
and receptor for advanced-glycation end products
(RAGE)-nuclear factor kappa B (NFκB)-dependent
release of IL-6 and TNF-α [46, 47]. Given this, the
enteric neuronal loss, detected by the decreased ex-
pression of HuC/D in the small intestine of mice
subjected to CPT-11-induced intestinal mucositis,
may be associated with the increase in the S100β
expression and subsequent release of proinflam-
matory cytokines and NO. Accordingly, the literature
describes the production of NO by peritoneal rats
macrophages stimulated with S100β, in a concentration-
dependent manner [48]. In addition, it has been demon-
strated that inducers of NO also induce the expression of
GFAP, through NO. The NO-coupled guanylate cyclase-
cyclic guanosine monophosphate (cGMP)-activated pro-
tein kinase pathway seems to be important in the GFAP
activation [41], suggesting that the upregulation of GFAP
expression in the ENS, induced by CPT-11 in the current
work, may follow the NO production.
The effects of CPT-11 in the ENS, as observed in
the present work, are at least partially related to mast
cell stimulation and degranulation, since decreased
expression of GPAF and S100β was observed when
compound 48/80 was administered to CPT-11-treated
mice, probably as a consequence of its protective ef-
fects on the small intestinal mucosa and submucosa
during the CPT-11-induced intestinal mucositis, illus-
trated by lower levels of inflammatory markers release
associated with reduced number of degranulated mast
cells in the three small intestine segments (jejunum
and ileum data not shown). A direct effect of mast
cell mediators on the ENS, however, should not be
ruled out. Mast cells are suggested to be key elements
in the neuro-immune interaction due to their close
localization to enteric neurons, vagal nervous fibers,
and spinal sensory nerves [21, 49]. In primary cul-
tures of neurons, it was showed that tryptase, a mast
cell protease, led to neuronal death via activation of
protease-activated receptor-2 (PAR-2) [22]. Further-
more, histamine, lipid mediators, cytokines, and adhe-
sion molecules act through paracrine pathways on the
enteric nervous system networks, which in turn regu-
late mast cell function [50]. Therefore, we speculate
that mast cells could account for neuronal death dur-
ing mucositis likely through similar mechanisms.
Conclusions
In summary, our results highlight the potential role of mast
cells during the inflammatory scenario induced by CPT-11
in the small intestine. These cells seem to release inflamma-
tory mediators that regulate glial cell and macrophages acti-
vation, leading to intestinal mucosa damage and reduction
of enteric neurons. However, more studies are needed to
work out how specifically the activation of mast cells after
exposure to CPT-11 leads to GI toxicity, and whether or
not mast cells play a direct role in the observed modifica-
tion of the ENS. In vitro studies are extremely important
for that investigation. In addition, it should be noted that,
although mouse models are powerful and effective to inves-
tigate the pathophysiology of many diseases, their use is not
directly applicable for the human. Further studies are
needed to propose a therapeutic strategy based on the data
presented in this study.
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